Risk group according to the NCCN guidelines

p-value

Very low-risk (VLR)

Low-risk (LR)

>65 y.o.

N = 19

≤65 y.o.

N = 26

>65 y.o.

N = 58

≤65 y.o.

N = 79

Age

Mean

(range)

69.5

(66 - 74)

60.3

(51 - 65)

70.1

(66 - 78)

59.1

(47 - 75)

-

PSA, ng/ml

Median

Mean

(range)

4.9

5.65

(3.2 - 8.6)

5.0

5.18

(1.1 - 8.3)

6.26

6.44

(4.0 - 9.92)

6.0

6.12

(3 - 10)

VLR ≤ 65 vs. LR ≤ 65, p = 0.01

PSA density

ng/ml/cc

Mean

(range)

0.108

(0.08 - 0.14)

0.117

(0.05 - 0.148)

0.20

(0.06 - 0.42)

0.23

(0.07 - 0.45)

VLR > 65 vs. VLR ≤ 65, p = 0.043

vs. LR ≤ 65, p < 0.0005

vs. LR > 65, p < 0.0005

VLR ≤ 65 vs. LR > 65, p < 0.0005

vs. LR > 65, p < 0.00054

LR ≤ 65 vs. LR > 65, p = 0.0589

No. of positive cores

1

2

3, 4

5, 6

≥7

16 (84.2%)

3 (15.8%)

-

-

-

18 (69.2%)

8 (30.8%)

-

-

-

23 (40%)

13 (22.4%)

16 (28%)

2 (3.5%)

4 (7%)

25 (31.6%)

17 (21.5%)

26 (32.9%)

8 (10%)

3 (4%)

-

Maximum cancer %

In biopsy cores

16.5 ± 13.7

(1 - 40)

20.0 ± 16.8

(3 - 50)

28.6 ± 26.7

(3 - 100)

26.8 ± 23.4

(3 - 95)

n.s.

Pathological stage, n (%)

pT2

pT3a

pT3b

pN+

16 (84.2%)

3 (15.8%)

-

-

24 (92.3%)

2 (7.7%)

-

-

49 (84.5%)

8 (13.8%)

-

1 (1.7%)

62 (78.5%)

17 (21.5%)

-

-

n.s.

Positive surgical margins, n (%)

4

(21%)

7

(26.9%)

21

(36.2%)

28

(35.4%)

n.s.

Gleason score

≤6

3 + 4

4 + 3

≥8

11 (57.9%)

8 (42.1%)

-

-

12 (46.1%)

13 (50%)

1 (3.9%)

-

20 (34.5%)

24 (41.4%)

9 (15.5%)

5 (8.6%)

23 (29.1%)

49 (62.0%)

6 (7.6%)

1 (1.3%)

VLR > 65 vs. LR ≤ 65, p = 0.013

Maximum diameter of largest cancer,

(mm)

Median (range)

5.5 (2 - 20)

12 (3 - 30)

18 (5 - 48)

15 (3 - 42)

VLR > 65 vs. LR > 65, p = 0.0101

vs. VLR ≤ 65, p = 0.0096

VLR ≤ 65 vs. LR > 65, p = 0.032